Current advances in transdermal delivery of drugs for Alzheimer's disease
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Thuy Trang Nguyen | - |
dc.contributor.author | Vo Van Giau | - |
dc.contributor.author | Tuong Kha Vo | - |
dc.date.available | 2020-02-27T19:43:16Z | - |
dc.date.created | 2020-02-06 | - |
dc.date.issued | 2017-03 | - |
dc.identifier.issn | 0253-7613 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/6383 | - |
dc.description.abstract | Alzheimer's disease (AD) is a common, progressive, fatal neurodegenerative disorder, which will play an increasingly important role both socially and financially in the aging populations. Treatments for AD show modest improvements in cognition and global functioning among patients. Furthermore, the oral administration of treating AD has had some drawbacks that decrease the medication adherence and efficacy of the therapy. Transdermal drugs are proposed as an alternative remedy to overcome the disadvantages of current pharmaceutical dosage options for this chronic disorder. They could have different strengths, such as offering a stable diffusion of active substance, avoiding the first pass metabolism, and reducing system adverse reactions. This article reviews the technical principles, novel techniques of transdermal delivery drug, and prospects for future development for the management of cognitive and behavioral dysfunctions in AD patients. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | WOLTERS KLUWER MEDKNOW PUBLICATIONS | - |
dc.relation.isPartOf | INDIAN JOURNAL OF PHARMACOLOGY | - |
dc.subject | LOW-FREQUENCY SONOPHORESIS | - |
dc.subject | IN-VITRO | - |
dc.subject | HUPERZINE-A | - |
dc.subject | CHOLINESTERASE INHIBITION | - |
dc.subject | DONEPEZIL HYDROCHLORIDE | - |
dc.subject | LIGUSTRAZINE PHOSPHATE | - |
dc.subject | DOUBLE-BLIND | - |
dc.subject | PATCH | - |
dc.subject | RIVASTIGMINE | - |
dc.subject | PHARMACOKINETICS | - |
dc.title | Current advances in transdermal delivery of drugs for Alzheimer's disease | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000404291900002 | - |
dc.identifier.doi | 10.4103/0253-7613.208143 | - |
dc.identifier.bibliographicCitation | INDIAN JOURNAL OF PHARMACOLOGY, v.49, no.2, pp.145 - 154 | - |
dc.identifier.scopusid | 2-s2.0-85021219676 | - |
dc.citation.endPage | 154 | - |
dc.citation.startPage | 145 | - |
dc.citation.title | INDIAN JOURNAL OF PHARMACOLOGY | - |
dc.citation.volume | 49 | - |
dc.citation.number | 2 | - |
dc.contributor.affiliatedAuthor | Thuy Trang Nguyen | - |
dc.contributor.affiliatedAuthor | Vo Van Giau | - |
dc.type.docType | Review | - |
dc.subject.keywordAuthor | Alzheimer&apos | - |
dc.subject.keywordAuthor | s disease | - |
dc.subject.keywordAuthor | controlled release | - |
dc.subject.keywordAuthor | patch | - |
dc.subject.keywordAuthor | permeation flux | - |
dc.subject.keywordAuthor | transdermal | - |
dc.subject.keywordPlus | LOW-FREQUENCY SONOPHORESIS | - |
dc.subject.keywordPlus | IN-VITRO | - |
dc.subject.keywordPlus | HUPERZINE-A | - |
dc.subject.keywordPlus | CHOLINESTERASE INHIBITION | - |
dc.subject.keywordPlus | DONEPEZIL HYDROCHLORIDE | - |
dc.subject.keywordPlus | LIGUSTRAZINE PHOSPHATE | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | PATCH | - |
dc.subject.keywordPlus | RIVASTIGMINE | - |
dc.subject.keywordPlus | PHARMACOKINETICS | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.